Vanda Pharmaceuticals Inc.

What they do

Vanda commercializes five products: Fanapt and BYSANTI for bipolar I disorder and schizophrenia, HETLIOZ for Non-24 and Smith-Magenis syndrome, PONVORY for relapsing multiple sclerosis, and NEREUS for motion-induced vomiting. The company also has a broad pipeline including late-stage programs for GLP-1-induced vomiting, social anxiety disorder, delayed sleep phase disorder, and major depressive disorder, as well as earlier-stage assets in immunology, oncology, and rare diseases.

Revenue drivers

• Fanapt — Oral tablets for schizophrenia and bipolar I disorder; 2025 net sales of $117.3M and Q2 2026 net sales of $36.0M, up 23% year-over-year; strongest growth driver.
• HETLIOZ — Capsules and oral suspension for Non-24 and SMS; 2025 net sales of $71.4M but declining due to generic competition (Q2 2026 down 66% year-over-year).
• PONVORY — Tablets for relapsing multiple sclerosis; 2025 net sales of $27.4M and Q2 2026 net sales of $7.9M, up 12% year-over-year.
• NEREUS — Capsules for prevention of motion-induced vomiting; launched in Q2 2026 with $1.0M sales in the quarter via direct-to-consumer web portal.

Recent performance

Total net product sales for Q2 2026 were $50.5M, down 4% year-over-year, excluding approximately $7.0M of HETLIOZ orders shipped late in June that will be recognized in Q3 2026. First-half 2026 sales were $102.2M, roughly flat versus $102.6M in the prior year. The company reported a pre-tax loss of $62.4M in Q2 2026 versus $34.9M in Q2 2025, reflecting heavy investment in launches and pipeline. Cash, cash equivalents, and marketable securities were $170.0M as of June 30, 2026, down $32.3M during the quarter. Full-year 2025 revenue was $216.1M with a net loss of $220.5M and diluted EPS of -$3.74.

Strategy

Management aims to maximize commercial success of existing products while advancing a late-stage pipeline and preparing multiple launches. Key priorities include commercializing BYSANTI (approved in Q1 2026, launch expected H2 2026), expanding NEREUS promotion, and seeking regulatory approval for Quimilza in GPP with a PDUFA date of December 12, 2026. The company also plans to moderate operating expenses from late 2026 into 2027 as Phase III programs wrap up. Partnerships and pharmacogenetics/genomics are part of the stated strategy to differentiate products and extend reach.

Risks

• HETLIOZ generic competition — HETLIOZ faces generic versions in the U.S. and sales fell 66% year-over-year in Q2 2026; increased competition could further erode revenue.
• Pipeline execution and regulatory uncertainty — Multiple late-stage trials (NEREUS in GLP-1, VQW-765, HETLIOZ DSPD, BYSANTI MDD) and the Quimilza BLA have binary outcomes; delays or failures could hurt valuation.
• Rising operating expenses and cash burn — Operating expenses have risen significantly due to launch preparations and pipeline advancement, driving a $62.4M pre-tax loss in Q2 2026 and a $32.3M quarterly cash decline.
• Dependence on a limited product portfolio — The company relies on a few commercial products, especially Fanapt, which accounted for over half of 2025 net sales; commercial underperformance of any one product would have a material impact.

Outlook

Management expects full-year 2026 total revenue of $240-$290 million, with cash sufficient to fund operations through at least the end of 2027. Phase III topline results for NEREUS in GLP-1-induced vomiting, VQW-765 in social anxiety, and HETLIOZ in delayed sleep phase disorder are expected by end-2026. The BYSANTI launch is planned for H2 2026, and the Quimilza PDUFA date is December 12, 2026. Operating expenses are expected to moderate from late 2026 and more substantially in 2027.